Rilvegostomig

• A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending
  2024-512195-35-00 Phase III 9 countries AstraZeneca AB
• A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel… Pending
  2024-519786-22-01 Phase I/II 7 countries AstraZeneca AB
• A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s… Pending
  2025-524843-11-00 Phase II 3 countries AstraZeneca AB
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o… Recruiting
  2023-508056-19-00 Phase III 13 countries AstraZeneca AB
• Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting
  2023-508057-19-00 Phase III 10 countries AstraZeneca AB
• A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy… Recruiting
  2025-523085-24-00 Phase III 7 countries AstraZeneca AB
• Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin… Recruiting
  2024-518210-81-00 Phase III 6 countries AstraZeneca AB
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting
  2024-517780-24-00 Phase III 10 countries AstraZeneca AB
• A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with… Recruiting
  2024-512583-57-00 Phase III 9 countries AstraZeneca AB
• A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting
  2024-514281-39-00 Phase III 9 countries AstraZeneca AB
• A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting
  2024-515008-38-00 Phase III 8 countries AstraZeneca AB
• A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting
  2023-505077-32-00 Phase III 7 countries AstraZeneca AB
• Master protocol of novel combinations in participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction … Recruiting
  2024-510977-27-00 Phase II 1 country AstraZeneca AB
• Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting
  2023-508852-21-00 Phase II 7 countries AstraZeneca AB
• A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting
  2023-504888-16-00 Phase I/II 5 countries AstraZeneca AB
• PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Ended
  2025-521302-17-00 Phase II/III 1 country Fondation Franc.Cancerologie Digestive
• Master protocol of novel agents or combinations as perioperative treatment in participants with locally advanced resectable gastroesophagea… Ended
  2024-516909-23-00 Phase II 2 countries AstraZeneca AB
• A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended
  2023-506054-20-00 Phase III 8 countries Astrazeneca AB
• Master Protocol of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobilia… Ended
  2022-502317-29-00 Phase II 2 countries AstraZeneca AB
• Phase 1b Study of Dato-DXd in Combination with Immunotherapy with or without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cance… Ended
  2023-505992-54-00 Phase I (Other) 4 countries Astrazeneca AB
• A trial to learn how safe rilvegostomig (AZD2936) is, how it moves throughout the body over time, and how well it works in adults with advan… Ended
  2023-508262-15-00 Phase I (FiH) 5 countries AstraZeneca AB

Showing 1–21 of 21 trials